Sequent Scientific Ltd.

NSE: SEQUENT | BSE: 512529 | ISIN: INE807F01027 |Industry: Pharmaceuticals
|Expensive Star
155.65 2.40 (1.57%)
NSE Nov 27, 2020 15:31 PM
Volume: 663.4K

Sequent Scientific Ltd.    
31 Jul 2020
Nirmal Bang Institutional
Sequent Scientific or SSLs 1QFY21 revenue at Rs3,103mn was higher than our estimate by 1.6%. Revenue grew by 11.6% YoY and was led by growth in both API and formulation sales across geographies, except the Emerging Markets (EM). There was a conscious decision to slow down in EMs considering the risk of bad debts. However, the situation is now normalizing and we should see sales in EMs back on track. Incrementally, the company has also entered into a distribution agreement with global animal health giant Zoetis for distribution of their products in India. The agreement gives SSL right to a portfolio of 13 brands (19 SKUs) amounting to Rs400mn in annual sales....
Sequent Scientific L.. has an average target of 186.00 from 2 brokers.
More from Sequent Scientific Ltd.